title: Innovative technique to reduce incidence of Frey's syndrome after parotid surgery.
abstract: Frey's syndrome was first described by Lucia Frey, a Polish neurologist in 1923. It is well accepted that it involves injury to the branches of the auriculotemporal nerve with subsequent aberrant regeneration. Due to this abnormal communication, the skin glands and vessels are always stimulated at the same time as eating and mastication, which results in symptoms such as flushing and sweating. The incidence of Frey's syndrome in the literature has been variously described from 6 to 96 per cent. We analyzed the chart of 18 patients who had parotidectomy from March 2002 to December 2009. All procedures were performed by a single surgeon at the same facility. A total of 16 superficial and three total parotidectomies were done; one patient had bilateral parotidectomy. Oxidized regenerated cellulose (Interceed) was used after 10 surgeries (study group) and no adjuvant was used after nine surgeries (control group). All of the surgeries were done using similar technique. All the patients were followed-up with for a period of about 6 months postoperatively. The absolute risk reduction associated with the placement of an Interceed was 11 per cent. The small number of cases (n = 19) and an empty cell limits statistical analysis (a Fisher's exact test revealed a P value of 0.44). Clearly the low number of procedures restricted the power to test these differences. The development of Frey's syndrome is a very disabling but under-reported complication. The placement of a temporary barrier like Interceed may help in the prevention of Frey's syndrome without increasing any complications.
authors.affiliation: Department of Surgery, Easton Hospital, Easton, Pennsylvania 18042, USA. neerajsingh11@gmail.com
authors.forename: Neeraj
authors.initials: N
authors.lastname: Singh
authors.forename: Monica
authors.initials: M
authors.lastname: Kohli
authors.forename: Harjeet
authors.initials: H
authors.lastname: Kohli
mesh_terms: D000236:Adenoma / Q000473:pathology / Q000601:surgery*; D002483:Cellulose, Oxidized / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010306:Parotid Gland / Q000601:surgery*; D010307:Parotid Neoplasms / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D013547:Sweating, Gustatory / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D002483:Cellulose, Oxidized; C060002:INTERCEED